A recurrent or metastatic HNSCC cohort will be also recruited in the TACTI-002 (two active immunotherapies) phase II study (NCT03625323) to assess the safety and efficacy of a combination of soluble LAG-3 fusion protein Eftilagimod alpha (IMP321) and pembrolizumab. The gene discussed is LAG3; the disease is head and neck squamous cell carcinoma.